SAT0025 THE EFFECT OF DIMETHYL FUMARATE ON PLASMABLAST DIFFERENTIATION TRANSCRIPTIONAL PROGRAMMES IN SYSTEMIC LUPUS ERYTHEMATOSUS

Background: Dimethyl fumarate (DMF), is an immunomodulatory drug approved for the treatment of Multiple Sclerosis (MS) and Psoriasis. The exact mechanism of action of DMF is not entirely known. Anti-inflammatory and immunomodulatory effects have been observed, including the upregulation of NRF-2, the inhibition of TIGAR and the block of the E2 ubiquitin-conjugating enzyme UBEL3. Further evidence from MS patients suggests a modulation on B cell activation. Although beneficial effects of DMF have been observed in animal models of lupus nephritis and limited cases human cutaneous lupus, the effect of DMF on B cell maturation transcriptional programmes in systemic Lupus Erythematosus (SLE) has …